![Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention | Journal of the American College of Cardiology Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/0afaeade-0d2c-4d80-a046-654791a357e8/gr4.jpg)
Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention | Journal of the American College of Cardiology
Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study | PLOS ONE
![Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions](https://www.jacc.org/cms/asset/e6dc3da7-9b8a-42c9-b7ed-81229dfe915f/gr3.jpg)
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
![Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet](https://www.thelancet.com/cms/attachment/69234b20-9c84-42ba-bbc2-8a6e3c87e1fc/gr1_lrg.gif)
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet
![Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet](https://www.thelancet.com/cms/attachment/da3e1393-85db-4116-bbdd-b3ad4e5114be/gr2.jpg)
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet
![Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology](https://bjcardio.co.uk/wp-content/uploads/2018/04/PIONEER-2-Figure-1.png)
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
![Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial - The Lancet Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2ed12575-9ecf-4084-97b8-f6f47df5b3da/gr1.gif)
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial - The Lancet
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril
![The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com](https://cf-images.us-east-1.prod.boltdns.net/v1/jit/5270290550001/b830587e-bedd-4562-b25a-e2ecc9580aac/main/1280x720/3m44s783ms/match/image.jpg)
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com
![Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions](https://www.jacc.org/cms/asset/0f878952-5093-4326-8522-37e5b401b7c1/gr4.jpg)
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions
![Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1936879819318552-gr4.jpg)